Herbacetin, A Constituent of Ephedrae herba, Suppresses the HGF-Induced Motility of Human Breast Cancer MDA-MB-231 Cells by Inhibiting c-Met and Akt Phosphorylation

Abstract

Ephedrae herba suppresses hepatocyte growth factor-induced cancer cell motility by inhibiting tyrosine phosphorylation of the hepatocyte growth factor receptor, c-Met, and the PI3K/Akt pathway. Moreover, Ephedrae herba directly inhibits the tyrosine-kinase activity of c-Met. Ephedrine-type alkaloids, which are the active component of Ephedrae herba, do not affect hepatocyte growth factor-c-Met-Akt signalling, prompting us to study other active molecules in the herb. We recently discovered herbacetin glycosides and found that their aglycon, herbacetin, inhibits hepatocyte growth factor-c-Met-Akt signalling. This study revealed a novel biological activity of herbacetin. Herbacetin suppressed hepatocyte growth factor-induced motility in human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation and directly inhibiting c-Met tyrosine kinase activity. The effects of herbacetin were compared to those of kaempferol, apigenin, and isoscutellarein, all of which have similar structures. Herbacetin inhibition of hepatocyte growth factor-induced motility was the strongest of those for the tested flavonols, and only herbacetin inhibited the hepatocyte growth factor-induced phosphorylation of c-Met. These data suggest that herbacetin is a novel Met inhibitor with a potential utility in cancer therapeutics.

Key words

herbacetin - c-Met - hepatocyte growth factor - cancer cell motility - Ephedrae herba - Ephedraceae

• References

• 1 Borgiel-Marek H, Kajdaniuk D, Niedzielska I, Kos-Kudla B, Tarabura-Dragon J, Marek B. Serum concentration of hepatocyte growth factor (HGF) in oral squamous cell carcinoma before and after surgery. Preliminary report. Endokrynol Pol 2008; 59: 467-470
• 2 Junbo H, Li Q, Zaide W, Yunde H. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In Vivo 1999; 13: 177-180
• 3 Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, Fonatsch C, Tsubouchi H, Hishida T, Daikuhara Y, Birchmeier W. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 1991; 88: 7001-7005
• 4 Eiichi G. Function and regulation of production of hepatocyte growth factor (HGF). Nippon Yakurigaku Zasshi 2002; 119: 287-294
• 5 Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3: S21-S35
• 6 Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103
• 7 Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009; 280: 1-14
• 8 Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-2214
• 9 Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res 2012; 35: 595-604
• 10 Hyuga S, Hyuga M, Yamagata S, Yamagata T, Hanawa T. Mao-to, a Kampo medicine, inhibits migration of highly metastatic osteosarcoma cells. J Tradit Med 2004; 21: 174-181
• 11 Hyuga S, Hyuga M, Nakanishi H, Ito H, Watanabe K, Oikawa T, Hanawa T. Maoto, Kampo medicine, suppresses the metastatic potential of highly metastatic osteosarcoma cells. J Tradit Med 2007; 24: 51-58
• 12 Hyuga S, Hanawa T. Basic research on the use of Kampo medicines to protect against cancer recurrence and metastasis. J Tradit Med 2013; 30: 19-26
• 13 Hyuga S, Shiraishi M, Hyuga M, Goda Y, Hanawa T. Ephedrae herba, a major component of maoto, inhibits the HGF-induced motility of human breast cancer MDA-MB-231 cells through suppression of c-Met tyrosine phosphorylation and c-Met expression. J Tradit Med 2011; 28: 128-138
• 14 Ministry of Health Law, Japan. The Japanese pharmacopoeia, 16th edition 2010. Tokyo: Ministry of Health Law; 2013: 1589
• 15 Amakura Y, Yoshimura M, Yamakami S, Yoshida T, Wakana D, Hyuga M, Hyuga S, Hanawa T, Goda Y. Characterization of phenolic constituents from Ephedra herb extract. Molecules 2013; 18: 5326-5334
• 16 Pangarova TT, Zapesochnaya GG, Nukhimovskii EL. Flavonoids of Rhodiola algida . Chem Nat Compd 1974; 10: 685-686
• 17 Husseina SAM, Barakatb HH, Nawar MAM, Willuhn G. Flavonoids from Ephedra aphylla . Phytochemistry 1997; 45: 1529-1532
• 18 Qiu SX, Lu ZZ, Luyengi L, Lee SK, Pezzuto JM, Farnsworth NR, Thompson LU, Fong HHS. Isolation and characterization of flaxseed (Linum usitatissimum) constituents. Pharm Biol 1999; 37: 1-7
• 19 Choe KI, Kwon JH, Park KH, Oh MH, Kim MH, Kim HH, Cho SH, Chung EK, Ha SY, Lee MW. The antioxidant and anti-inflammatory effects of phenolic compounds isolated from the root of Rhodiola sachalinensis A. BOR. Molecules 2012; 17: 11484-11494
• 20 Qiao Y, Xiang Q, Yuan L, Xu L, Liu Z, Liu X. Herbacetin induces apoptosis in HepG2 cells: Involvements of ROS and PI3K/Akt pathway. Food Chem Toxicol 2013; 51: 426-433
• 21 Hyuga S, Yamagata S, Takatsu Y, Hyuga M, Nakanishi H, Furukawa K, Yamagata T. Suppression by ganglioside GD1a of migration capability, adhesion to vitronectin and metastatic potential of highly metastatic FBJ-LL cells. Int J Cancer 2004; 83: 685-691
• 22 Kedrin D, van Rheenen J, Hernandez L, Condeelis J, Segall J. Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 2007; 12: 143-152
• 23 Previdi S, Abbadessa G, Dalo F, France DS, Broggini M. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012; 11: 214-223
• 24 Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2009; 21: 470-476
• 25 Chin YR, Toker A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell 2010; 38: 333-344
• 26 Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 2008; 226: 178-191
• 27 Lolli G, Cozza G, Mazzorana M, Tibaldi E, Cesaro L, Donella-Deana A, Meggio F, Venerando A, Franchin C, Sarno S, Battistutta R, Pinna LA. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry 2012; 51: 6097-6107
• 28 Cuccioloni M, Bonfili L, Mozzicafreddo M, Cecarini V, Eleuteri AM, Angeletti M. Sanguisorba minor extract suppresses plasmin-mediated mechanisms of cancer cell migration. Biochim Biophys Acta 2012; 1820: 1027-1034
• 29 Labbe D, Provencal M, Lamy S, Boivin D, Gingras D, Beliveau R. The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. J Nutr 2009; 139: 646-652
• 30 Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 2013; 19: 2310-2318
• 31 Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 2013; 4: 9-17
• 32 Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043
• 33 Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013; 31: 1089-1096